Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Nature Communications
|
August 2, 2022
Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes
Samah Hayek, Yatir Ben-Shlomo, Noa Dagan, et al.
The New England Journal of Medicine
|
August 25, 2021
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Noam Barda, Noa Dagan, Yatir Ben-Shlomo, et al.
Nature Communications
|
September 8, 2020
Developing a COVID-19 mortality risk prediction model when individual-level data are not available
Noam Barda, Dan Riesel, Amichay Akriv, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
June 28, 2024
Effectiveness and safety of molnupiravir in the intended-use population: an observational cohort study
Wiessam Abu Ahmad, Ronen Arbel, Yael Wolff Sagy, et al.
Infectious Diseases and Therapy
|
May 10, 2024
Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups
Samah Hayek, Joseph Levy, Galit Shaham, et al.
Indian Journal of Dermatology, Venereology and Leprology
|
August 19, 2025
Bidirectional association between vitiligo and melasma: A large-scale population-based study
Shany Sherman, Hadar Duskin-Bitan, Tamir Agiv, et al.
The New England Journal of Medicine
|
June 29, 2022
BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
Chandra J Cohen-Stavi, Ori Magen, Noam Barda, et al.
Infectious Diseases and Therapy
|
January 6, 2025
Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period
Samah Hayek, Joseph Levy, Galit Shaham, et al.
The New England Journal of Medicine
|
August 24, 2022
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Ronen Arbel, Yael Wolff Sagy, Moshe Hoshen, et al.
Nature Medicine
|
January 31, 2023
Real-world effectiveness of a single dose of mpox vaccine in males
Yael Wolff Sagy, Roy Zucker, Ariel Hammerman, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Nature Communications
|
August 2, 2022
Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes
Samah Hayek, Yatir Ben-Shlomo, Noa Dagan, et al.
The New England Journal of Medicine
|
August 25, 2021
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Noam Barda, Noa Dagan, Yatir Ben-Shlomo, et al.
Nature Communications
|
September 8, 2020
Developing a COVID-19 mortality risk prediction model when individual-level data are not available
Noam Barda, Dan Riesel, Amichay Akriv, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
June 28, 2024
Effectiveness and safety of molnupiravir in the intended-use population: an observational cohort study
Wiessam Abu Ahmad, Ronen Arbel, Yael Wolff Sagy, et al.
Infectious Diseases and Therapy
|
May 10, 2024
Implementation of AZD7442 (Tixagevimab/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups
Samah Hayek, Joseph Levy, Galit Shaham, et al.
Indian Journal of Dermatology, Venereology and Leprology
|
August 19, 2025
Bidirectional association between vitiligo and melasma: A large-scale population-based study
Shany Sherman, Hadar Duskin-Bitan, Tamir Agiv, et al.
The New England Journal of Medicine
|
June 29, 2022
BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
Chandra J Cohen-Stavi, Ori Magen, Noam Barda, et al.
Infectious Diseases and Therapy
|
January 6, 2025
Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period
Samah Hayek, Joseph Levy, Galit Shaham, et al.
The New England Journal of Medicine
|
August 24, 2022
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Ronen Arbel, Yael Wolff Sagy, Moshe Hoshen, et al.
Nature Medicine
|
January 31, 2023
Real-world effectiveness of a single dose of mpox vaccine in males
Yael Wolff Sagy, Roy Zucker, Ariel Hammerman, et al.
Page
of 5